Propofol Injection, Emulsion
NDC 51662-1471
Product Information
Propofol is a ANDA-approved product labeled by Hf Acquisition Co Llc, Dba Healthfirst. This medication is typically used as a general anesthesia [pe]. It is supplied as a injection, emulsion for intravenous administration. This product entry covers the primary NDC 51662-1471 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 51662-1471?
What are the uses of this product?
What are Active Ingredients of this product?
- PROPOFOL 10 mg/mL - An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PROPOFOL (UNII: YI7VU623SF)
- PROPOFOL (UNII: YI7VU623SF) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SOYBEAN OIL (UNII: 241ATL177A)
- GLYCERIN (UNII: PDC6A3C0OX)
- EGG PHOSPHOLIPIDS (UNII: 1Z74184RGV)
- SODIUM BENZOATE (UNII: OJ245FE5EU)
- BENZYL ALCOHOL (UNII: LKG8494WBH)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1808222 - propofol 500 MG in 50 ML Injection
- RxCUI: 1808222 - 50 ML propofol 10 MG/ML Injection
- RxCUI: 1808222 - propofol 500 MG per 50 ML Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.